[
  {
    "ts": null,
    "headline": "Johnson & Johnson Goes to Trial on Third Talc Bankruptcy Plan",
    "summary": "Johnson & Johnson Goes to Trial on Third Talc Bankruptcy Plan",
    "url": "https://finnhub.io/api/news?id=552ba1815bc22ef4357a898953418872759b36ce72840a60da7486619725d271",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739899320,
      "headline": "Johnson & Johnson Goes to Trial on Third Talc Bankruptcy Plan",
      "id": 132785430,
      "image": "",
      "related": "JNJ",
      "source": "DowJones",
      "summary": "Johnson & Johnson Goes to Trial on Third Talc Bankruptcy Plan",
      "url": "https://finnhub.io/api/news?id=552ba1815bc22ef4357a898953418872759b36ce72840a60da7486619725d271"
    }
  },
  {
    "ts": null,
    "headline": "American Century Equity Income Fund Q4 2024 Commentary",
    "summary": "Growth stocks outpaced their value counterparts during the quarter, even as some investors sought lower-volatility positions. Read more here.",
    "url": "https://finnhub.io/api/news?id=24059a49384deda6cb03e2a6a8cc929779b10eefc7554041ca94201b12b89841",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739865600,
      "headline": "American Century Equity Income Fund Q4 2024 Commentary",
      "id": 132767113,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1376140848/image_1376140848.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Growth stocks outpaced their value counterparts during the quarter, even as some investors sought lower-volatility positions. Read more here.",
      "url": "https://finnhub.io/api/news?id=24059a49384deda6cb03e2a6a8cc929779b10eefc7554041ca94201b12b89841"
    }
  },
  {
    "ts": null,
    "headline": "Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon",
    "summary": "Genmab's Q4 2024 results impress with $897.4M revenue and 29% growth. GMAB's balance sheet is strong with nearly $3 billion in cash. Read more here.",
    "url": "https://finnhub.io/api/news?id=c1d6b14105926a08ff7e19ff286d926c37916f912b70debf4d6b1fa4ee9261f2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739845553,
      "headline": "Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon",
      "id": 132765944,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/170096596/image_170096596.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Genmab's Q4 2024 results impress with $897.4M revenue and 29% growth. GMAB's balance sheet is strong with nearly $3 billion in cash. Read more here.",
      "url": "https://finnhub.io/api/news?id=c1d6b14105926a08ff7e19ff286d926c37916f912b70debf4d6b1fa4ee9261f2"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson: Rich History Of Excellence Poised To Endure",
    "summary": "Johnson & Johnson is well-diversified across thriving healthcare segments, with promising FDA approvals. Read why I assign a Strong Buy rating for JNJ stock.",
    "url": "https://finnhub.io/api/news?id=2009007b3a8fa13fd665e3645d0dcb6a750e72709c6e6463f20513c66552b02c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739845013,
      "headline": "Johnson & Johnson: Rich History Of Excellence Poised To Endure",
      "id": 132765917,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1225119943/image_1225119943.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Johnson & Johnson is well-diversified across thriving healthcare segments, with promising FDA approvals. Read why I assign a Strong Buy rating for JNJ stock.",
      "url": "https://finnhub.io/api/news?id=2009007b3a8fa13fd665e3645d0dcb6a750e72709c6e6463f20513c66552b02c"
    }
  }
]